Deep Vein Thrombosis - A Pipeline Analysis Report

This pipeline analysis report provides detailed insights into the clinical trials landscape of the drug development for deep vein thrombosis including molecules at pre-clinical and discovery stage. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentations such as therapy, route of administration, and target.

Overview of the drug development pipeline for deep vein thrombosis

It has been observed that deep vein thrombosis is a common disease that can lead to complications such as pulmonary embolism and death. The approach to the diagnosis of deep vein thrombosis has evolved over the years. Usually, anticoagulation therapy is used for the treatment of deep vein thrombosis, whereas procedures such as thrombolysis and placement of inferior vena cava filters are reserved for special situations. In the US, almost 900,000 people are affected by deep vein thrombosis every year. Out of which, about 60,000 to 100,000 Americans die due to deep vein thrombosis/pulmonary embolism. Monotherapy is emerging as the most effective approach for the treatment of deep vein thrombosis.

According to this pipeline analysis report, all the drug molecules in the pipeline are being developed for deep vein thrombosis. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

Want a bigger picture? Get a FREE sample of this report now!

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of deep vein thrombosis. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are:

• CarboMimetics
• DAIICHI SANKYO
• Genentech

Therapeutic assessment of the drug development pipeline for deep vein thrombosis by route of administration

• Oral
• Intravenous
• Unknown

The oral route of administration (ROA) involves the delivery of the drug directly into the mouth cavity and in the intravenous technique, the molecules are administered into the veins, which will have a more direct effect on the target cells.

Therapeutic assessment of the drug development pipeline for deep vein thrombosis by therapy

• Monotherapy

According to this pipeline analysis report, all the molecules that are currently in the drug pipeline for deep vein thrombosis are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.

Key questions answered in the report include

• What are the gene therapy molecules in the various development stages for deep vein thrombosis?
• What are the companies that are currently involved in the development of drug molecules for deep vein thrombosis?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.